Galectin-1, -3, -7 Expressions in Congenital and Acquired Pediatric Cholesteatomas Compared to External Auditory Canal Skin

Marc Vander Ghinst, MD1 · Myriam Remmelink, MD2 · Anne-Laure Mansbach, MD3 · Sergio Hassid, MD1 Georges Choufani, MD1

Departments of 1Otorhinolaryngology and 2Pathology, Erasmus University Hospital, Université Libre de Bruxelles, Brussels; 3Department of Otorhinolaryngology, Reine Fabiola Children’s Hospital, Brussels, Belgium

INTRODUCTION

Cholesteatoma is defined by a keratinizing squamous epithelium in the middle ear cavities. Although cholesteatoma is a benign disease, it can invade neighboring tissues and often recur even if surgical resection is considered to be complete. Cholesteatoma is traditionally classified as either acquired, essentially due to a chronic otitis process, or congenital. Congenital cholesteatoma are classically presented as a white mass behind an intact tympanic membrane, typically in the anterosuperior quadrant (1). Although acquired and congenital cholesteatoma are histologically identical, they do not share the same etiopathogenesis.

Congenital cholesteatoma is thought to occur due to secondary failure of normal involution of the epidermoid formation. This collection of stratified squamous epidermoid cells appears during fetal development (1). Many other mechanisms have also been proposed, such as metaplastic origins or a migration of epithelial cells from the external auditory canal (2, 3).

Key Words. Middle ear cholesteatoma, Galectins, Immunohistochemistry

Objectives. There is a classical distinction based on clinical criteria between acquired and congenital cholesteatomas. To determine if these two types of lesions show different immunohistochemical features, we have studied the expression patterns of three distinctive galectins (animal lectins implied especially in cellular proliferation and apoptosis) in both types of cholesteatomas and compared it to their expression patterns in external auditory canal skin.

Methods. Our study is based on nine acquired and eight congenital cholesteatomas, obtained from children during ear surgery. Six specimens of normal adult auditory meatal skin served as control. Specimens were analyzed by immunohistochemistry using monoclonal antibodies with galectin-1 and galectin-3, and a polyclonal antibody with galectin-7.

Results. We did not observe any differences in the galectin distribution pattern between congenital and acquired pediatric cholesteatomas. Compared to the control group, cholesteatomas present some particular features. There was no expression of galectin-1 and a lower expression of galectin-3 in the epithelium. Furthermore, we observed a preferentially nuclear distribution of galectin-7 in cholesteatomas, whereas it is essentially cytoplasmic in the control group.

Conclusion. The data reported in this study suggest, on the basis of a lesser marked galectin-3 in cholesteatomas epithelium compared with an external auditory canal skin, that an immature keratinocytes population is at the origin of these lesions and that galectin-3 and galectin-7 play a part in the capacity as apoptosis modulators. Our study does not establish a difference in the galectin expressions of congenital and acquired cholesteatomas, but it constitutes however an additional argument in favor of the “undifferentiated” origin of keratinocytes in cholesteatomas.
In the same way, the origin of acquired cholesteatoma remains under discussion. Among the various advanced theories, the most probable one considers the epithelial migration as the origin of the pathology. This migration can either start from the margins of a tympanic perforation, or from the retraction of the tympanic membrane (4).

The particularly aggressive behavior of cholesteatomas can be explained - at least partially - by disorders in growth regulation and cellular death of keratinocytes. The apoptosis of excessive keratinocytes is related to modifications of expression of various proteins, in particular the phosphoprotein p53 (5). Recurrent cholesteatomas can be distinguished from nonrecurrent on the basis of the quantity and the distribution from apoptotic cells. Among proteins implied in the regulation of this population of keratinocytes, galectin-3 seems to hold a particular role (6).

Galectins are members of an animal lectin family defined by shared consensus amino acid sequences and an affinity for β-galactose-containing oligosaccharides. To date, 15 different galectins have been identified. They are implied in varied biological phenomena such as embryonic development, immune response, cellular proliferation or apoptosis. They also play a similar role to that of adhesion molecules on intercellular interactions and extracellular matrix-cell interaction (7-12).

Although, the expression of galectins has been observed in many normal and pathological tissues studies (including cholesteatomas for galectin-1, -3, and -8) (6), no previous study has been interested in the expression of these proteins in congenital and acquired cholesteatoma compared to external auditory canal skin.

Based on the observation that histologically similar tumors can present different immunohistochemical patterns (13), it seemed to us interesting to study the immunohistochemical behavior of congenital and acquired cholesteatomas on the basis of their expressions of galectin-1, -3, and -7 and to compare it with the expression patterns of these galectins in external auditory canal skin.

**MATERIALS AND METHODS**

**Histopathologic and clinical data**

Eight congenital cholesteatomas (six males, two females, average age 7.8 years) and 9 acquired pediatric cholesteatomas (eight males, one female, average age 9.6 years) were obtained immediately after middle ear surgery. In all cases, it was a first surgical cure of cholesteatoma. Six congenital cholesteatomas were obtained from the ENT Department of the “Reine Fabiola Children’s Hospital” (Brussels, Belgium). The others were obtained from the ENT Department of the “Erasmus University Hospital” (Brussels, Belgium) and all were subjected to the standard diagnosis routine in the Department of Pathology of this same hospital. All the congenital cholesteatomas exhibited a classical otomicroscopic aspect for this disease, i.e., a white mass behind an intact tympanic membrane. Specimens of normal adult auditory meatal skin (n=6) obtained during autopsy served as controls. All autopsies were performed within a 24 hours postmortem delay to ensure a good preservation and staining of tissue antigens (14).

The specimens were immediately fixed in 4% formaldehyde and embedded in paraffin. Sections were cut at a thickness of 5 μm and processed for H&E staining using routine protocols. This study was approved by the ethical committee of the Erasmus University Hospital (Ref P2010/069).

**Immunohistochemistry**

The 5-μm-thick sections were subjected to standard immunohistochemical, as previously detailed (15-17). The immunohistochemical expression was visualized by means of streptavidin-biotin-peroxidase complex kit reagents (BioGenex, San Ramon, CA, USA) with diaminobenzidine/H2O2 as the chromogenic substrate. Finally, the sections were counterstained with haematoxylin. Galectin-1 and galectin-3 expression was evidenced by means of two specific monoclonal antibodies, respectively (Novocastra, Newcastle, UK; dilution 1:100). Galectin-7 was immunolocalized in tissues with a polyclonal rabbit anti-human galectin-7 antibody, as detailed elsewhere (15). Negative controls had the primary antibodies replaced by non-immune serum (Dako, Glostrup, Denmark).

**Immunohistochemistry: evaluation**

We performed a semi-quantitative (for galectin-1 and galectin-7) and quantitative (for galectin-3) evaluation. For each slide, the entire tissue was analyzed. Two independent observers conducted on blind-labeled sections the assessment of the immunohistochemical staining of galectin-1 and -7.

The assessment of the immunohistochemical staining was considered as follows: 1) For galectin-1, according to the presence or the absence of staining within the stroma and/or the epithelium; 2) For galectin-3, a quantitative analysis is accomplished by computer-aided microscopy (×200 magnification; Histolab, Alphelys, France). The two studied variables were the labeling index (LI) and the index of transmitted intensity. The LI refers to the percentage of tissue area specifically stained by a given histochemical marker. The Index of transmitted intensity denotes staining intensity; 3) For galectin-7, the score was established after counting the number of labeled nuclei compared to all nuclei. The staining was considered nuclear if more than 10% of nuclei were labeled in the epithelium.

**Statistical analysis**

Due to the restricted number of cases and the obviously similar immunohistochemical staining in both of the cholesteatomas groups, we decided to compare directly the cholesteatomas (acquired and congenital) groups with the control group. Concern-
ing the statistical analysis of the galectin-3 data, the differences between independent groups of quantitative data were analyzed by the Mann-Whitney non-parametric test. Concerning galectin-1 and -7 (two binary variables), Fisher’s exact test were used. All the statistical analyses were carried out using Statistica (Statsoft, Tulsa, OK, USA).

**RESULTS**

We did not observe any differences in the galectin distribution pattern between congenital and acquired pediatric cholesteatomas (Table 1).

For galectin-1, a significant difference \( (P=0.00002, \text{Fisher’s exact test}) \) is observed between the cholesteatoma and the external auditory canal skin group. In fact, cholesteatoma’s epithelium does not express galectin-1, unlike the external ear skin specimens. Each specimen from both groups presented a stromal staining for galectin-1 (Fig. 1).

For galectin-3, the LI \( (P=0.0033, \text{Mann-Whitney non-parametric test}) \) as well as the index of transmitted intensity \( (P=0.0026) \) are significantly different between both groups (Fig. 2). Indeed, external auditory canal skin presented an intense and wider galectin-3 staining compared with acquired and congenital cholesteatomas. The staining in the external auditory canal skin group was particularly intense at intercellular junctions (Fig. 3).

For galectin-7, the cholesteatoma group (acquired and congenital) presented a predominant nuclear staining, while the control group presented a cytoplasmic predominant staining (Fig. 4). Moreover, the distribution of cells whose nucleus was positive was distributed heterogeneously, with some areas rich in labeled nucleus. This however, was statistically relevant \( (P=0.00009, \text{Table 1. Galectin-1, -3, and -7 distribution patterns in external auditory canal (EAC) skin, acquired and congenital cholesteatoma}) \)

| Galectin-1 | Acquired cholesteatoma | Congenital cholesteatoma |
|------------|------------------------|--------------------------|
| Staining in epithelium and stroma | Absence of staining in the epithelium staining in stroma | Absence of staining in the epithelium staining in stroma |
| Galectin-3 | Intense staining in epithelium | Mild to moderate staining in epithelium | Mild to moderate staining in epithelium |
| Galectin-7 | Cytoplasmic staining in the epithelium | Intense nuclear staining and moderate cytoplasmic staining in the epithelium | Intense nuclear staining and moderate cytoplasmic staining in the epithelium |

Fig. 1. Morphological aspect of the immunohistochemical staining for galectin-1 \((\times 400)\). (A) External auditory canal, (B) acquired cholesteatoma, (C) congenital cholesteatoma. st, stroma; ep, epithelium.

Fig. 2. Labeling index (LI) and index of transmitted intensity for galectin-3 in the three histological groups.
Fisher’s exact test).

**DISCUSSION**

The main result of this study is that acquired and congenital cholesteatomas exhibit the same galectin distribution patterns. The comparative analysis of the immunohistochemical behavior of these two forms of cholesteatomas is an interesting method to obtain information on their possible origins. Although a distinction between the two types of cholesteatomas could be recently established on the basis of difference in length of telomeres (18), there is currently no other evidence that these two groups of cholesteatomas show a difference in biological properties. For example, the cytokeratins expression does not differ according to whether the cholesteatoma is congenital or acquired (19). Our study reaches the same conclusion regarding the expressions of galectin-1, -3, and -7.

**Galectins and cholesteatomas**

If the presence of galectin-1 and -3 is already documented in skin and cholesteatomas (6, 20), no study has yet looked at galectins expression analysis in cholesteatomas in comparison with skin from the external auditory canal. Moreover, galectin-7 has never been studied in cholesteatoma. Galectin-1 is expressed in many cellular types and plays a role in varied biological phenomena, such as proliferation, apoptosis and cellular adhesion (7-9, 20). Contrary to what had been noted by Sheikholeslam-Zadeh et al. (6), which had shown a marked presence of galectin-1 in cholesteatoma epithelium, we have observed an absence of marking of galectin-1 within cholesteatoma epithelium. But their stromas, as well as the epithelium and the stromas of external auditory canal skin, expressed in galectin-1. These contradictory results are probably explained by a difference between the antibodies used: we employed a monoclonal anti-galectin-1 antibody, whereas a polyclonal antibody was used in their experiments. The monoclonal antibodies, resulting from a lymphocy-
To conclude, the data reported in this study suggest that on the basis of a lesser marked galectin-3 in cholesteatomas epithelium compared with an external auditory canal skin that an immature keratinocytes population is at the origin of these lesions and that galectin-3 and galectin-7 play a part in the capacity as apoptosis modulators. If our study does not establish a difference in the galectin expressions of congenital and acquired cholesteatomas, it constitutes however an additional argument in favor of the “undifferentiated” origin of keratinocytes in cholesteatomas.

To establish more precisely the role of galectins and the factors influencing their expression in cholesteatomas, and to determine possible biological differences between congenital and acquired specimens, a broader study with a larger sample group would be necessary.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Levenson MJ, Michaels L, Parisier SC, Juarbe C. Congenital cholesteatomas in children: an embryologic correlation. Laryngoscope. 1988 Sep;98(9):949-55.
2. Olszewska E, Wagner M, Bernal-Sprekelsen M, Ebmeyer J, Dazert S, Hildmann H, et al. Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol. 2004 Jan;261(1):6-24.
3. Tos M. A new pathogenesis of mesotympanic (congenital) cholesteatoma. Laryngoscope. 2000 Nov;110(11):1890-7.
4. Broekaert D. The problem of middle ear cholesteatoma: etiology, genetics and pathobiology - a review. Acta Otorhinolaryngol Belg. 1991;45(4):355-67.
5. Choufani G, Mahillon V, Decaestecker C, Lequeux T, Danguy A, Salmond I, et al. Determination of the levels of expression of saredolectin and calycin and of the percentages of apoptotic but not proliferating cells to enable distinction between recurrent and nonrecurrent cholesteatomas. Laryngoscope. 1999 Nov;109(11):1825-31.
6. Sheikholeslam-Zadeh R, Decaestecker C, Delbrouck C, Danguy A, Salmond I, Zick Y, et al. The levels of expression of galectin-3, but not of galectin-1 and galectin-8, correlate with apoptosis in human cholesteatomas. Laryngoscope. 2001 Jun;111(6):1042-7.
7. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med (Berl). 1998 May;76(6):402-12.
8. Elota MT, Chiesa ME, Alberti AF, Mordoh J, Fink NE. Galectin-1 receptors in different cell types. J Biochem. 2005;12(1):13-29.
9. Scott K, Weinberg C. Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj J. 2004;19(7-9):467-77.
10. Dunic J, Dabic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006 Apr;1760(4):616-35.
11. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta. 2009 Sep;1752(2-3):263-73.
12. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J. 2004;19(7-9):527-35.
13. Plic P, Vanmuylder N, Lefranc F, Heizmann CW, Hassid S, Salmond I, et al. Differential expression of $100$ calcium-binding proteins in epi-
dermoid cysts, branchial cysts, craniopharyngiomas and cholesteatomas. Histopathology. 2003 Apr;42(4):387-94.
14. Knudsen LM, Pallesen G. The preservation and loss of various non-haematopoietic antigens in human post-mortem tissues as demonstrated by monoclonal antibody immunohistological staining. Histopathology. 1986 Oct;10(10):1007-14.
15. Rorive S, Eddafali B, Fernandez S, Decaestecker C, Andre S, Kaltner H, et al. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol. 2002 Dec;15(12):1294-301.
16. Mathieu A, Saal I, Vuckovic A, Ranay V, Vereerstraen P, Kaltner H, et al. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2005 Sep;18(9):1264-71.
17. D’Haene N, Maris C, Sandras F, Dehou MF, Remmelink M, Decaestecker C, et al. The differential expression of galectin-1 and galectin-3 in normal lymphoid tissue and non-Hodgkin’s and Hodgkin’s lymphomas. Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3):431-43.
18. Kojima H, Miyazaki H, Shiwa M, Tanaka Y, Moriyama H. Molecular biological diagnosis of congenital and acquired cholesteatoma on the basis of differences in telomere length. Laryngoscope. 2001 May;111(5):867-73.
19. Olszewska E, Lautermann J, Koc C, Schwaab M, Dazert S, Hildmann H, et al. Cytokeratin expression pattern in congenital and acquired pediatric cholesteatomas. Eur Arch Otorhinolaryngol. 2005 Sep;262(9):731-6.
20. Sarafian V, Jans R, Poumay Y. Expression of lysosome-associated membrane protein 1 (Lamp-1) and galectins in human keratinocytes is regulated by differentiation. Arch Dermatol Res. 2006 Jul;298(2):73-81.
21. Dabbs DJ. Diagnostic immunohistochemistry. New York: Churchill Livingstone; 2002.
22. Saussez S, Decaestecker C, Lorfevre F, Chevalier D, Mortuaires G, Kaltner H, et al. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcimomas. Histopathology. 2008 Mar;52(4):483-93.
23. Akimoto Y, Hirabayashi J, Kasai K, Hirano H. Expression of the endogenous 14-kDa beta-galactoside-binding lectin golectin in normal human skin. Cell Tissue Res. 1995 Apr;280(1):3-10.
24. Lacina L, Plzakova Z, Smetana K Jr, Stork J, Kaltner H, Andre S. Glycophenotype of psoriatic skin. Folia Biol (Praha). 2006;52(1-2):10-5.
25. Simon P, Decaestecker C, Choufani G, Delbrouck C, Danguy A, Salmon I, et al. The levels of retinoid RARbeta receptors correlate with galectin-1, -3 and -8 expression in human cholesteatomas. Hear Res. 2001 Jun;156(1-2):1-9.
26. Haake AR, Cooklis M. Incomplete differentiation of fetal keratinocytes in the skin equivalent leads to the default pathway of apoptosis. Exp Cell Res. 1997 Feb;231(1):83-95.
27. Saegusa J, Hsu DK, Liu W, Kuwabara I, Kuwabara Y, Yu L, et al. Galectin-3 protects keratinocytes from UVB-induced apoptosis by enhancing AKT activation and suppressing ERK activation. J Invest Dermatol. 2008 Oct;128(10):2403-11.
28. Delorge S, Saussez S, Pec P, Devroede B, Marchant H, Burchert M, et al. Correlation of galectin-3/galectin-3-binding sites with low differentiation status in head and neck squamous cell carcinomas. Otolaryngol Head Neck Surg. 2000 Jun;122(6):834-41.
29. Polya K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997 Sep;389(6648):300-5.
30. Kuwabara I, Kuwabara Y, Yang RV, Schuler M, Green DR, Zuraw BL, et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem. 2002 Feb;277(3):3487-97.